315 related articles for article (PubMed ID: 20002781)
1. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
2. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
[TBL] [Abstract][Full Text] [Related]
3. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
4. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
Grossberg R; Zhang Y; Gross R
J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
Smith CJ; Phillips AN; Dauer B; Johnson MA; Lampe FC; Youle MS; Tyrer M; Staszewski S
HIV Med; 2009 Jan; 10(1):19-27. PubMed ID: 19018880
[TBL] [Abstract][Full Text] [Related]
6. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
[TBL] [Abstract][Full Text] [Related]
7. How reliable is an undetectable viral load?
Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B;
HIV Med; 2009 Sep; 10(8):470-6. PubMed ID: 19459990
[TBL] [Abstract][Full Text] [Related]
8. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC;
Antivir Ther; 2008; 13(1):77-85. PubMed ID: 18389901
[TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
10. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
11. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
Manavi K; Scott G
Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
[TBL] [Abstract][Full Text] [Related]
12. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.
García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682
[TBL] [Abstract][Full Text] [Related]
13. Impact of a modified directly administered antiretroviral treatment intervention on virological outcome in HIV-infected patients treated in Burkina Faso and Mali.
Pirkle CM; Boileau C; Nguyen VK; Machouf N; Ag-Aboubacrine S; Niamba PA; Drabo J; Koala S; Tremblay C; Rashed S
HIV Med; 2009 Mar; 10(3):152-6. PubMed ID: 19245536
[TBL] [Abstract][Full Text] [Related]
14. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
16. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
[TBL] [Abstract][Full Text] [Related]
17. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
18. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
[TBL] [Abstract][Full Text] [Related]
19. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
[TBL] [Abstract][Full Text] [Related]
20. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
